Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2431 to 2445 of 7684 results

  1. Iclepertin for treating cognitive impairment associated with schizophrenia ID6483

    Awaiting development [GID-TA11647] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Compression products for treating venous leg ulcers: late stage assessment

    In development [GID-HTE10048] Expected publication date: 27 August 2025

    Health technology evaluations
    In development

  3. Vosoritide for treating achondroplasia in children and young people under 18 years [ID3807]

    Awaiting development [GID-TA10700] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Pneumonia: diagnosis and management (update)

    In development [GID-NG10357] Expected publication date: TBC

    NICE guideline
    In development

  5. Rehabilitation for chronic neurological disorders including acquired brain injury

    In development [GID-NG10181] Expected publication date: 16 July 2025

    NICE guideline
    In development

  6. Vutrisiran for treating transthyretin-related amyloidosis with cardiomyopathy ID6470

    In development [GID-TA11598] Expected publication date: TBC

    Technology appraisal guidance
    In development

  7. Linaclotide acetate for treating Chronic idiopathic constipation [TS ID 12005]

      Status ...

    Technology appraisal guidance
    Topic selection

  8. Enfortumab vedotin with pembrolizumab for first-line treatment of unresectable or metastatic urothelial cancer who are eligible for platinum-containing chemotherapy [ID6332]

    In development [GID-TA11233] Expected publication date: 04 June 2025

    Technology appraisal guidance
    In development

  9. Baloxavir marboxil for Influenza

    Awaiting development [GID-TA11646] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Evinacumab for treating homozygous familial hypercholesterolemia in children aged 5 to 11 TS ID 11806

      Status ...

    Technology appraisal guidance
    Topic selection

  11. Topical antimicrobial dressings for infected leg ulcers in people aged 16 and over: Late stage assessment

    In development [GID-HTE10041] Expected publication date: 22 May 2025

    Health technology evaluations
    In development

  12. Inhaled treprostinil for treating pulmonary hypertension caused by interstitial lung disease ID6459

    In development [GID-TA11572] Expected publication date: TBC

    Technology appraisal guidance
    In development

  13. Ribociclib with an aromatase inhibitor for adjuvant treatment of hormone receptor-positive, HER2-negative early breast cancer [ID6153]

    In development [GID-TA11090] Expected publication date: 18 June 2025

    Technology appraisal guidance
    In development

  14. Mirvetuximab soravtansine for treating folate receptor alpha-positive platinum-resistant advanced epithelial ovarian, fallopian tube or primary peritoneal cancer ID6442

    In development [GID-TA11424] Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. Depemokimab for treating severe eosinophilic asthma in people 12 years and over ID6447

    Awaiting development [GID-TA11553] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development